Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
- Study HIC#:2000025172
- Last Updated:01/01/0001
Yale is participating in this phase III research study that is testing a new stem cell therapy treatment for perianal fistulas with Crohn’s Disease.
You may qualify if:
- You are between the ages of 18 to 75
- Have been diagnosed with Crohn’s Disease for at least 6 months
- Are not having symptoms of Crohn’s Disease but have perianal fistula(s) that have not responded to treatment
- Age18 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Elizabeth Ruggiero
- Phone Number: 1-203-785-4576
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of this phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn's disease over a period of 24 weeks and a follow-up period up to 52 weeks.
Eligibility Criteria
You may qualify if:
- You are between the ages of 18 to 75
- Have been diagnosed with Crohn’s Disease for at least 6 months
- Are not having symptoms of Crohn’s Disease but have perianal fistula(s) that have not responded to treatment
